Katherine Poinsatte, PhD,  —

In a “challenging case,” clinicians found a mutation in the membrane cofactor protein gene, or MCP/CD46, in a 23-year-old man with atypical hemolytic uremic syndrome (aHUS). In reporting the case, the researchers stressed the “critical role of genetic testing” in patient evaluations, highlighting the need to be aware of…

Bone abnormalities were reported in two teenage girls who were on long-term treatment with Soliris (eculizumab) for atypical hemolytic uremic syndrome (aHUS) associated with a deficiency of the complement factor H (FH). Clinicians are unsure whether these previously undescribed bone abnormalities, including pain, deformities, and joint swelling, were…

Soliris (eculizumab), an approved drug for atypical hemolytic uremic syndrome (aHUS), successfully treated a rare case of the disease in a girl, age 14 months, in China, according to a case study. After eight doses of the therapy, the levels of self-reactive antibodies against complement factor H —…